Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors

NCT02028507 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

693

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Palbociclib
DRUG: Capecitabine
DRUG: Exemestane
DRUG: Fulvestrant

Sponsor

Spanish Breast Cancer Research Group

Collaborators

[object Object]
[object Object]